Novel Treatment Approaches for Locally Advanced Pancreatic Cancer
Despite decades of research, pancreatic cancer remains essentially incurable for patients with unresectable tumors. In the United States, most patients with locally advanced pancreatic cancer are treated with chemotherapy alone or combined with conventionally fractionated radiotherapy. Regardless of the treatment strategy, average survival for these patients is less than 1 year, indicating that the current approaches are indisputably inadequate. For locally advanced pancreatic cancer patients, effective local-regional control is not only crucial for any hope at long-term survival, but also for symptom management. The aim of this paper is to highlight abstracts from the 2014 ASCO Gastrointestinal Cancers Symposium that demonstrate the use of novel local-regional therapies in locally advanced pancreatic cancer. Abstracts #317, #328, and #361 describe their results with an advanced method of delivering radiation called stereotactic body radiation therapy (SBRT). In these studies, patients treated with combined chemotherapy and SBRT had exceptional local control rates and acceptable toxicity. An innovative alternative to radiation for local-regional treatment is presented in Abstract #270. This study shows encouraging results from a phase I investigation of a regionally delivered siRNA that targets the K-rasG12D mutation. Investigation of novel approaches such as those presented here holds the greatest promise for improving treatment of this deadly disease.
Image: Tufts Medical Center. Boston, MA, USA
American Cancer Society. Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013.
Huguet F, Andre T, Hammel P, Artru P, Balosso J, Selle F, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007 Jan 20;25(3):326-31. [PMID: 17235048].
Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): A multicentre, randomised, phase 2 trial. Lancet Oncol. 2013 Apr;14(4):317-26. [PMID: 23474363].
Hammel P, Huguet F, Van Laethem JL, Goldstein D, Glimelius B, et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. J Clin Oncol 31,2013 (suppl; abstr #LBA4003).
Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009 Feb 1;115(3):665-72. [PMID: 19117351].
Schellenberg D, Kim J, Christman-Skieller C, Chun CL, Columbo LA, Ford JM, et al. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):181-8. [PMID: 21549517].
Polistina F, Costantin G, Casamassima F, Francescon P, Guglielmi R, Panizzoni G, et al. Unresectable locally advanced pancreatic cancer: A multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol. 2010 Aug;17(8):2092-101. [PMID:20224860].
Rwigema JC, Parikh SD, Heron DE, Howell M, Zeh H, Moser AJ, et al. Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol. 2011 Feb;34(1):63-9. [PMID: 20308870].
Chuong MD, Springett GM, Freilich JM, Park CK, Weber JM, Mellon EA, et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):516-22. [PMID: 23562768].
Pollom EL, Alagappan M, Chan C, Shultz D, Kunz PL, Koong A, et al. Outcomes and toxicity of SBRT for patients with unresectable pancreatic adenocarcinoma. J Clin Oncol 32, 2014 (suppl 3; abstr 317).
Moningi S, Raman SP, Dholakia AS, Hacker-Prietz A, Pawlik TM, Zheng L, et al. Stereotactic body radiation therapy for pancreatic cancer: Single institutional experience. J Clin Oncol 32, 2014 (suppl 3; abstr 328).
Gurka MK, Kim CM, Haddad NG, Carroll J, Charabaty AC, Jackson PG, et al. Stereotactic body radiation therapy (SBRT) combined with chemotherapy for locally advanced pancreatic adenocarcinoma. J Clin Oncol 32, 2014 (suppl 3; abstr 361).
Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004 Apr 15;22(8):1430-8. [PMID: 15084616].
Fleming JB, Shen GL, Holloway SE, Davis M, Brekken RA. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: Justification for K-ras-directed therapy. Mol Cancer Res. 2005 Jul;3(7):413-23. [PMID: 16046551].
Golan T, Hubert A, Shemi A, Segal A, Khvalevsky EZ, Domb A, et al. Novel K-ras-directed therapy in combination with chemotherapy for locally advanced pancreatic adenocarcinoma. J Clin Oncol 32, 2014 (suppl 3; abstr 270).
Brunner TB, Cengel KA, Hahn SM, Wu J, Fraker DL, McKenna WG, et al. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: The role of K-ras. Cancer Res. 2005 Sep 15;65(18):8433-41. [PMID: 16166322].
Copyright (c) 2014 Daniel Gorovets, Muhammad Wasif Saif, Kathryn Huber
This work is licensed under a Creative Commons Attribution 4.0 International License.As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.